Evidence map›Paper›PMID 40391158›Full record

ArticleFrontiers in oncology2025

Repurposing riluzole as an anti-osteosarcoma agent.

Okkeun Jung, Vinagolu K Rajasekhar, Syeda Maryam Azeem, Shraddha ChandThakuri, Beatrice Norton, John H Healey, Shahana Mahajan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Okkeun Jung *Program in Biology, The CUNY Graduate Center, New York, NY, United States.
Vinagolu K Rajasekhar *Orthopedic Research Laboratory, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States.
Syeda Maryam Azeem *Program in Biology, The CUNY Graduate Center, New York, NY, United States.
Shraddha ChandThakuri *Department of Medical Laboratory Sciences, Hunter College, City University of New York, New York, NY, United States.
Beatrice NortonDepartment of Chemistry at Hunter College, City University of New York, New York, NY, United States.
John H HealeyOrthopedic Research Laboratory, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States.
Shahana MahajanProgram in Biology, The CUNY Graduate Center, New York, NY, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Investigating drug targets and improving drug delivery for anti-cancer treatment of osteosarcomaSC1GM131929 · NIGMS · HUNTER COLLEGE · PI MAHAJAN, SHAHANA SULTANA · 2020 to 2023
$1.6M
NCI NIH HHS P30 CA008748NIGMS NIH HHS SC1 GM131929
6 · The paper itself

Abstract

We have studied riluzole, a glutamate-release inhibitor, as a novel anti-osteosarcoma agent. YAP (Yes-associated protein) is recruited by

Indexed as

metastasisMMP2osteosarcomapatient-derived xenograft cell linesreactive oxygen speciesriluzole

Identifiers

PMID40391158
PMCPMC12086166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.